Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study

OBJECTIVES: Pembrolizumab plus platinum-based chemotherapy and pembrolizumab monotherapy (PM) both become standard of care in patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) greater than 50%. This study aimed to figure ou...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Oncol
Päätekijät: Chen, Ya, Wang, Yanan, Yang, Zhengyu, Hu, Minjuan, Zhang, Yanwei, Qian, Fangfei, Zhang, Wei, Zhang, Bo, Han, Baohui
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2021
Aiheet:
Oncology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8273651/
https://ncbi.nlm.nih.gov/pubmed/34262873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.691519
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia